Background and aims: to evaluate in POAG patients the hypotensive and neuroprotective effects of brimonidine 0.2% in monotherapy or in combination with previous antiglaucomatous treatment. Methods: 44 POAG patients (88 eyes; mean age 64.1±9,4ys) with early-moderate glaucomatous damage, in treatment with topical antiglaucomatous drugs (mean IOP 21.7±2.1mmHg ) were enrolled in the study. 20 patients (40 eyes) switched to brimonidine 0.2% bid in monotherapy; in 24 patients (48 eyes) brimonidine 0.2% bid was added to previous treatment (76% of eyes were treated with timolol 0.5%). IOP and visual acuity were evaluated before and after six months of brimonidine therapy. At six months control contrast sensitivity was measured with MAV Professional. The test was structured using Snellen letters at three different spatial frequencies (0,1 VA, 0,5 VA, and maximum VA) in order to obtain a curve. The results were compared with an homogeneous group of 18 POAG patients (34 eyes; 17.3±2.4mmHg; mean age 65.7±4.4ys) in treatment (>6 months) with timolol 0.5% and 44 normal subjects age and sex matched. Statistical analysis was conducted using a paired t test. Results: significant reduction in IOP values (-19.7% monotherapy, p<0.05; -18.5% in combination, p<0.05) was observed in brimonidine treated eyes. In this group contrast sensitivity for all spatial frequencies was significantly higher than timolol treated eyes (p<0,05).Conclusions: the results show a positive effect of brimonidine in monoterapy and also in combination with other antiglaucomatous drugs on contrast sensitivity due to his neuroprotective property.
Brimonidine 0,2% in primary open angle glaucoma: hypotensive and neuroprotective effects
ROLLE, Teresa;FEA, Antonio Maria;
2007-01-01
Abstract
Background and aims: to evaluate in POAG patients the hypotensive and neuroprotective effects of brimonidine 0.2% in monotherapy or in combination with previous antiglaucomatous treatment. Methods: 44 POAG patients (88 eyes; mean age 64.1±9,4ys) with early-moderate glaucomatous damage, in treatment with topical antiglaucomatous drugs (mean IOP 21.7±2.1mmHg ) were enrolled in the study. 20 patients (40 eyes) switched to brimonidine 0.2% bid in monotherapy; in 24 patients (48 eyes) brimonidine 0.2% bid was added to previous treatment (76% of eyes were treated with timolol 0.5%). IOP and visual acuity were evaluated before and after six months of brimonidine therapy. At six months control contrast sensitivity was measured with MAV Professional. The test was structured using Snellen letters at three different spatial frequencies (0,1 VA, 0,5 VA, and maximum VA) in order to obtain a curve. The results were compared with an homogeneous group of 18 POAG patients (34 eyes; 17.3±2.4mmHg; mean age 65.7±4.4ys) in treatment (>6 months) with timolol 0.5% and 44 normal subjects age and sex matched. Statistical analysis was conducted using a paired t test. Results: significant reduction in IOP values (-19.7% monotherapy, p<0.05; -18.5% in combination, p<0.05) was observed in brimonidine treated eyes. In this group contrast sensitivity for all spatial frequencies was significantly higher than timolol treated eyes (p<0,05).Conclusions: the results show a positive effect of brimonidine in monoterapy and also in combination with other antiglaucomatous drugs on contrast sensitivity due to his neuroprotective property.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
